Ibandronic acid Chemical Properties

Melting point:

113-115°C

Boiling point:

587.8±60.0 °C(Predicted)

Density 

1.449±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,Store in freezer, under -20°C

solubility 

Aqueous Base (Slightly), Methanol (Slightly), Water (Slightly)

pka

1.60±0.10(Predicted)

form 

Solid

color 

White to Off-White

Stability:

Hygroscopic

CAS DataBase Reference

114084-78-5(CAS DataBase Reference)

EPA Substance Registry System

Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5)

Ibandronic acid Usage And Synthesis

Description

This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.

Chemical Properties

White Solid

Originator

Boehringer Mannheim (Germany)

Uses

Labelled Ibandronic Acid (I120000). A bisphosphonate antiresorptive agent. Bone resorption inhibitor.

Uses

A bisphosphonate antiresorptive agent. Bone resorption inhibitor.

Uses

A biphosphonate bone resorption inhibitor.

Uses

A labeled biphosphonate bone resorption inhibitor.

brand name

Bondronat

Clinical Use

Bisphosphonate:

Reduction of bone damage in bone metastases in breast cancer

Hypercalcaemia of malignancy

Postmenopausal osteoporosis

Metabolism

After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine. There is no evidence that ibandronic acid is metabolised in animals or humans. The absorbed fraction of ibandronic acid is removed from the circulation via bone absorption (estimated to be 40-50% in postmenopausal women) and the remainder is eliminated unchanged by the kidney. The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces. Renal clearance accounts for 50-60% of total clearance and is related to creatinine clearance. The difference between the apparent total and renal clearances is considered to reflect the uptake by bone.

Ibandronic acid(114084-78-5)Related Product Information

• Folic acid
• CHLOROPHOSPHONAZO III
• Disodium pamidronate
• Amino tris(methylene phosphonic acid)
• Ethyl 2-(Chlorosulfonyl)acetate
• Hyaluronic acid
• Amylamine
• Methyldiethoxyphosphine
• Stearic acid
• Zoledronic acid
• Citric acid
• 1-Hydroxyethylidene-1,1-diphosphonic acid
• Ascoric Acid
• Dimethyl methylphosphonate
• Ibandronate sodium monohydrate
• Ibandronate sodium
• 3-(N-Methylpentylamino)propionic acid hydrochloride
• Tetramethyl Ibandronate